Long-term observations and salvage operations on patients with T2N0M0 squamous cell carcinoma of the glottic larynx treated with radiation therapy alone

Acta Oto-Laryngologica

Volumn 132, Issue 5, 2012, Pages 546-551

  Furusaka, Tohru ^a,b   Matuda, Hiroshi ^b   Saito, Tsutomu ^a   Katsura, Yoshihisa ^c   Ikeda, Minoru ^a  

^a NIHON UNIVERSITY   (Japan)

^b TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^c SURUGADAI NIHON UNIVERSITY HOSPITAL   (Japan)

Author keywords

Larynx preservation rate; Long term survival rate; Salvage operation

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; DERMATITIS; DISEASE COURSE; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; LARYNGECTOMY; LARYNX CARCINOMA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION FIELD; SALVAGE THERAPY; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; GLOTTIS; HUMANS; JAPAN; LARYNGEAL NEOPLASMS; LARYNGECTOMY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TIME FACTORS;

EID: 84859738263     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.3109/00016489.2011.646008     Document Type: Article

References (14)

1. Le QTX, Fu KK, Kroll S, Ryu JK, Quivey JM, Meyler TS, et al. Influence of fraction size, total dose and overall time on local control of T1-T2 glottic carcinoma. Int J Radiat Oncol Biol Phys 1997;39:115-26.
2. Warde P, O'Sullivan B, Bristow RG, Panzarella T, Keane TJ, Gullane PJ, et al. T1/T2 glottic cancer managed by external beam radiotherapy; the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys 1998;41: 347-53.
3. Mendenhall WM, Amdur RJ, Morris CG, Hinermann RW. T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol 2001;19:4029-36.
4. Sobin LH, Gospodarowicsz MK, Wittekind Ch. 2009. TNM classification of malignant tumours. 7th edition. New York: John Wiley & Sons. p 39-45.
5. Izuno I, Sone S, Oguchi M, Kiyono K, Takei K. Treatment of early vocal cord carcinoma with 60Co gamma rays, 8/10 MV x-rays, or 4 MV x-rays-are the results different? Acta Oncol 1990;29:637-9.
6. Inoue T, Inoue T, Chatani M, Teshima T. Irradiated volume and arytenoid edema after radiotherapy for T1 glottic carcinoma. Strahlenther Onkol 1992;168:23-6.
7. Teshima T, Chatani M, Inoue T. Radiation therapy for early glottic cancer (T1N0M0): II. Prospective randomized study concerning radiation field. Int J Radiat Oncol Biol Phys 1990; 18:119-23.
8. Harwood AR, Hawkins NV, Rider WD, Bryce DP. Radiotherapy of early glottic cancer-I. Int J Radiat Oncol Biol Phys 1979;5:473-6.
9. Mlynarek A, Kost K, Gesser R. Radiotherapy versus surgery for early T1-T2 glottic carcinoma. J Otolaryngol 2006;35: 413-19.
10. Piccirillo JF, Wells CK, Sasaki CT, Feinstein AR. New clinical severity staging system for cancer of larynx. Fiveyear survival rates. Ann Otol Rhinol Laryngol 1994;103:83-92.
11. Hafidh M, Tibbo J, Trites J, Corsten G, Hart RD, Nasser J, et al. Radiotherapy for T1 and T2 laryngeal cancer: the Dalhousie University experience. J Otolaryngol Head Neck Surg 2009;38:434-9.
12. Nomiya T, Nemoto K, Wada H, Takai Y, Yamada S. Longterm results of radiotherapy for T1a and T1bN0M0 glottic carcinoma. Laryngoscope 2008;118:1417-21.
13. Taguchi T, Tukuda M, Mikami Y, Horiuchi C, Ishitoya J-I, Katori H. Concurrent chemoradiotherapy with carboplatin and uracil-ftegafur in patients with stage two (T2N0M0) squamous cell carcinoma of the glottic larynx. J Laryngol Otol 2006;120:478-81.
14. Breitbart WS, Holland JC. 1989. Head and neck cancer. In Holland JC, Rowland JH, editors. Handbook of psychooncology: psychological care of the patient with cancer. New York: Oxford University Press. p 232-9.